Free tool
FAERS Monitor: Eprontia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214679 or its brand name (Eprontia, Topiramate). Reports on generic versions are filed under their own applications.
Reports
50,531
Serious
38,698
77% of reports
Hospitalization
14,416
Death reported
5,656
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective7,042
- off label use5,694
- headache3,683
- nausea3,328
- fatigue3,196
- product use in unapproved indication2,623
- pain2,574
- migraine2,544
- dizziness2,419
- seizure2,273
- condition aggravated2,215
- diarrhoea2,210
- vomiting2,190
- drug intolerance2,143
- depression1,972
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 139 |
| 2005 | 254 |
| 2006 | 207 |
| 2007 | 196 |
| 2008 | 383 |
| 2009 | 775 |
| 2010 | 941 |
| 2011 | 1,213 |
| 2012 | 1,395 |
| 2013 | 1,214 |
| 2014 | 1,551 |
| 2015 | 2,420 |
| 2016 | 2,928 |
| 2017 | 2,678 |
| 2018 | 3,542 |
| 2019 | 3,947 |
| 2020 | 3,671 |
| 2021 | 3,717 |
| 2022 | 3,597 |
| 2023 | 3,911 |
| 2024 | 4,561 |
| 2025 | 4,463 |
| 2026 | 2,823 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,628 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| migraineSignal | 2,544 | 11.4 | 10.9 | 23,514 |
| drug intoleranceSignal | 2,143 | 9.4 | 9.0 | 15,836 |
| seizureSignal | 2,273 | 8.3 | 8.0 | 14,456 |
| product use in unapproved indicationSignal | 2,623 | 4.4 | 4.3 | 7,000 |
| depressionSignal | 1,972 | 3.6 | 3.5 | 3,764 |
| condition aggravatedSignal | 2,215 | 3.0 | 2.9 | 3,067 |
| off label useSignal | 5,694 | 2.7 | 2.7 | 6,407 |
| headacheSignal | 3,683 | 2.5 | 2.4 | 3,249 |
| drug ineffectiveSignal | 7,042 | 2.2 | 2.2 | 5,072 |
| dizzinessSignal | 2,419 | 2.0 | 1.9 | 1,276 |
| vomiting | 2,190 | 1.9 | 1.9 | 1,020 |
| nausea | 3,328 | 1.8 | 1.7 | 1,114 |
| pain | 2,574 | 1.7 | 1.7 | 843 |
| fatigue | 3,196 | 1.7 | 1.7 | 977 |
| diarrhoea | 2,210 | 1.4 | 1.4 | 289 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.